PPI Use Ups NSAID-Induced Small Bowel Injury

This article originally appeared here.
Share this content:
PPI Use Ups NSAID-Induced Small Bowel Injury
PPI Use Ups NSAID-Induced Small Bowel Injury

FRIDAY, May 27, 2016 (HealthDay News) -- Proton pump inhibitors (PPIs) increase the risk of nonsteroidal anti-inflammatory drug-induced small bowel injury, according to a study published in the June issue of Clinical Gastroenterology and Hepatology.

Ema Washio, from Kyushu University in Fukuoka, Japan, and colleagues randomized healthy participants to receive the cyclooxygenase (COX)-2 inhibitor celecoxib plus placebo for two weeks (30 participants) or celecoxib plus the PPI rabeprazole for two weeks (27 participants). Participants were assessed by capsule endoscopy at the start of the study and two weeks after celecoxib administration.

The researchers found that the proportion of participants who developed small bowel injury was higher in the COX-2 + PPI group than the COX-2 + placebo group (44.4 versus 16.7 percent, respectively; P = 0.04). The risk of small bowel injury was increased for individuals in the COX-2 + PPI group versus the COX-2 + placebo group (relative risk, 2.67). Each member of the COX-2 + PPI group had a greater number of erosions than each member of the COX-2 + placebo group (P = 0.02). There was no between-group difference in the number of ulcers. Mucosal injury in the jejunum occurred in 26 percent of the COX-2 + PPI group compared with none of the COX-2 + placebo group (P = 0.003).

"In a randomized, controlled trial, PPIs increased the risk of short-term nonsteroidal anti-inflammatory drug-induced small bowel injury," the authors write.

The study was funded by Eisai.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »